Neurological Sciences

, Volume 36, Supplement 1, pp 33–35

Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience

MIGRAINE - NEWS IN PATHOPHYSIOLOGY

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin, a potent toxin produced by the anaerobic bacterium clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperhidrosis, is used for patients suffering from chronic migraine. In this study, a group of patients suffering from chronic migraine with medication overuse was treated with onabotulinum toxin A (Botox) to verify its efficacy for chronic migraine. The results confirmed the efficacy of onabotulinum toxin A (Botox) when used at the dosage of 155 UI according to the PREEMPT protocol. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of onabotulinum toxin A (Botox) and to assess its use in clinical practice, in particular in migraine field.

Keywords

Onabotulinum toxin A (Botox) Chronic migraine (CM) with medication overuse (MO) PREEMPT study 

References

  1. 1.
    Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483CrossRefPubMedGoogle Scholar
  2. 2.
    Dodick D, Turkel C, De Gryse R et al (2010) Onabotulinum toxinA for treatment of chronic migraine: pooled results from double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936CrossRefPubMedGoogle Scholar
  3. 3.
    Diener HC, Dodick D, Aurora S et al (2010) Onabotulinum toxinA for treatment of chronic migraine: results from the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalagia 30:804–814CrossRefGoogle Scholar
  4. 4.
    Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of onabotulinum toxin A for chronic migraine : a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418CrossRefPubMedGoogle Scholar
  5. 5.
    Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274–283CrossRefPubMedGoogle Scholar
  6. 6.
    Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793CrossRefPubMedGoogle Scholar
  7. 7.
    Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15CrossRefPubMedGoogle Scholar
  8. 8.
    Silberstein S, Blumenfeld A, Cady R, Turner I, Lipton R, Diener HC, Aurora S, Sirimanne M, DeGryse R, Turkel C, Dodick D (2013) Onabotulinum toxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 15(331(1–2)):48–56CrossRefGoogle Scholar
  9. 9.
    Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRefGoogle Scholar
  10. 10.
    Ashkenazi A (2010) Botulinum toxin type A for chronic migraine. Curr Neurol Neurosci Rep 10:140–146CrossRefPubMedGoogle Scholar
  11. 11.
    Rothrock J, Bloudek LM, Rothrock DA, Varon SF (2014) Real-world economic impact of onabotulinum toxin A in patients with chronic migraine. Headache 54:1565–1573CrossRefPubMedGoogle Scholar
  12. 12.
    Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J (2014) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. doi:10.1177/0333102414561873 Google Scholar
  13. 13.
    Silberstein SD, Dodick WD, Aurora SK, Dienere H-C, DeGryse RE, Lipton RB, Turkel CC (2014) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2013-307149 Google Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  1. 1.Headache CenterNeurological Institute “C. Besta”MilanItaly

Personalised recommendations